Inclusion Criteria:

          1. Male and female patients ≥ 1 and ≤ 29 years of age at time of consent.

          2. AML in second or greater relapse, post-transplant relapse, or chemotherapy-refractory
             disease. Specifically:

               1. Second or greater relapse defined as flow cytometric confirmation of myeloid
                  leukemia of at least 0.1% after second documented complete remission; OR

               2. Any detectable disease post-allogeneic transplant with flow cytometric
                  confirmation (MRD) of myeloid leukemia of at least 0.1%; OR

               3. Refractory disease, defined as persistent bone marrow involvement with >5% blasts
                  after two courses of induction chemotherapy for patients at initial presentation
                  or >5% bone marrow blasts after one course of re-induction chemotherapy for
                  patients who have relapsed after previously achieving a CR.

          3. Subjects must have a suitable stem cell donor available who may donate cells in the
             event the subject needs to undergo an allogeneic HCT. Donor may be matched or
             mismatched and must be found to be suitable according to the institution's standard
             criteria; donors must be fully cleared to proceed as the donor.

          4. Adequate organ function defined as:

             a. A serum creatinine based on age/gender b. Adequate liver function i. ALT ≤ 5 x ULN
             ii. Total bilirubin ≤ 3 x ULN iii. ALT and/or bilirubin results that exceed this range
             are acceptable if, in the opinion of the physician-investigator (or as confirmed by
             liver biopsy), the abnormalities are directly related to ALL infiltration of the
             liver.

             c. Must have a minimum level of pulmonary reserve defined as ≤ Grade 1 dyspnea and <
             Grade 3 hypoxia; DLCO ≥ 40% (corrected for anemia) if PFTs are clinically appropriate
             as determined by the treating investigator d. Left Ventricular Shortening Fraction
             (LVSF) ≥ 28% or Ejection Fraction (LVEF) ≥ 45% confirmed by ECHO, or adequate
             ventricular function documented by a scan or a cardiologist. In cases where
             quantitative assessment of LVSF/LVEF is not possible, a statement by the cardiologist
             that the ECHO shows qualitatively normal ventricular function will suffice.

          5. Adequate performance status defined as Lansky or Karnofsky score ≥ 50

          6. Signed informed consent must be obtained.

          7. No contraindications for leukapheresis (unless apheresis product previously acquired).

          8. Subjects of reproductive potential must agree to use acceptable birth control methods.

        Exclusion Criteria:

          1. Pregnant or lactating (nursing) women.

          2. Patients with relapsed AML with t(15:17).

          3. Patients must be > 6 months from alloHSCT.

          4. HIV infection.

          5. Active hepatitis B or hepatitis C infection.

          6. Active acute or chronic graft-versus-host disease (GVHD) requiring systemic therapy

          7. Concurrent use of systemic steroids at the time of cell infusion or cell collection or
             a condition, in the treating physician's opinion, that is likely to require steroid
             therapy during collection or after infusion. Steroids for disease treatment at times
             other than cell collection or at the time of infusion are permitted. Use of
             physiologic replacement hydrocortisone or inhaled steroids is permitted as well.

          8. Any uncontrolled active medical disorder that would preclude participation as
             outlined.

          9. Uncontrolled active infection

         10. Subjects with CNS3 disease that is progressive on therapy or with CNS parenchymal
             lesions that may increase the risk of CNS toxicity. Subjects with adequately treated
             CNS leukemia are eligible.

         11. Known history of allergy or hypersensitivity to study product excipients (human serum
             albumin, DMSO, and Dextran 40).

         12. Patients with any prior history of myeloproliferative neoplasm.

         13. Patients with somatic JAK2 V617F mutation by PCR or next generation sequencing.